NanoViricides Total Stockholder Equity vs Other Current Liab Analysis
NNVC Stock | USD 1.10 0.01 0.90% |
NanoViricides financial indicator trend analysis is infinitely more than just investigating NanoViricides recent accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether NanoViricides is a good investment. Please check the relationship between NanoViricides Total Stockholder Equity and its Other Current Liab accounts. Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in NanoViricides. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in real. For information on how to trade NanoViricides Stock refer to our How to Trade NanoViricides Stock guide.
Total Stockholder Equity vs Other Current Liab
Total Stockholder Equity vs Other Current Liab Correlation Analysis
The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of NanoViricides Total Stockholder Equity account and Other Current Liab. At this time, the significance of the direction appears to have weak contrarian relationship.
The correlation between NanoViricides' Total Stockholder Equity and Other Current Liab is -0.18. Overlapping area represents the amount of variation of Total Stockholder Equity that can explain the historical movement of Other Current Liab in the same time period over historical financial statements of NanoViricides, assuming nothing else is changed. The correlation between historical values of NanoViricides' Total Stockholder Equity and Other Current Liab is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Total Stockholder Equity of NanoViricides are associated (or correlated) with its Other Current Liab. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Other Current Liab has no effect on the direction of Total Stockholder Equity i.e., NanoViricides' Total Stockholder Equity and Other Current Liab go up and down completely randomly.
Correlation Coefficient | -0.18 |
Relationship Direction | Negative |
Relationship Strength | Insignificant |
Total Stockholder Equity
The total equity held by shareholders, calculated as the difference between a company's total assets and total liabilities. It represents the net value of the company owned by shareholders.Other Current Liab
Most indicators from NanoViricides' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into NanoViricides current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in NanoViricides. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in real. For information on how to trade NanoViricides Stock refer to our How to Trade NanoViricides Stock guide.At present, NanoViricides' Issuance Of Capital Stock is projected to increase significantly based on the last few years of reporting.
2021 | 2022 | 2023 | 2024 (projected) | Reconciled Depreciation | 723.3K | 747.5K | 859.7K | 772.2K | Interest Income | 11.9K | 355.8K | 409.2K | 429.7K |
NanoViricides fundamental ratios Correlations
Click cells to compare fundamentals
NanoViricides Account Relationship Matchups
High Positive Relationship
High Negative Relationship
NanoViricides fundamental ratios Accounts
2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
Other Current Liab | 630.8K | 55.8K | 260.1K | 377.2K | 433.8K | 706.2K | |
Total Current Liabilities | 2.2M | 351.1K | 412.8K | 534.3K | 614.4K | 583.7K | |
Total Stockholder Equity | 21.8M | 29.9M | 23.1M | 14.9M | 17.1M | 15.3M | |
Retained Earnings | (105.6M) | (114.4M) | (122.5M) | (131.1M) | (118.0M) | (112.1M) | |
Accounts Payable | 380.7K | 200.0K | 58.0K | 157.1K | 141.4K | 274.0K | |
Common Stock Total Equity | 69.2K | 76.9K | 9.1K | 11.5K | 10.4K | 9.8K | |
Common Stock Shares Outstanding | 5.6M | 10.9M | 11.5M | 11.6M | 13.4M | 14.0M | |
Other Stockholder Equity | 127.3M | 144.3M | 145.6M | 145.9M | 167.8M | 176.2M | |
Total Liab | 2.2M | 351.1K | 412.8K | 2.0M | 2.3M | 4.3M | |
Accumulated Other Comprehensive Income | (3.2M) | (3.9M) | (4.6M) | (5.0) | (4.5) | (4.73) | |
Common Stock | 9.1K | 11.5K | 11.6K | 116.0 | 104.4 | 99.18 | |
Total Assets | 23.9M | 30.3M | 23.5M | 16.9M | 19.4M | 20.7M | |
Property Plant And Equipment Net | 9.5M | 9.1M | 8.7M | 8.1M | 9.3M | 6.2M | |
Net Debt | (12.6M) | (20.4M) | (14.0M) | (8.1M) | (7.3M) | (7.7M) | |
Cash | 13.7M | 20.5M | 14.1M | 8.1M | 9.4M | 13.7M | |
Non Current Assets Total | 9.9M | 9.4M | 9.1M | 8.5M | 9.7M | 6.7M | |
Non Currrent Assets Other | 25.9K | 3.5K | 42.4K | 14.4K | 12.9K | 12.3K | |
Cash And Short Term Investments | 13.7M | 20.5M | 14.1M | 8.1M | 9.4M | 13.7M | |
Liabilities And Stockholders Equity | 23.9M | 30.3M | 23.5M | 16.9M | 19.4M | 20.7M | |
Non Current Liabilities Total | 1.5M | 295.3K | 152.7K | 1.5M | 1.4M | 1.3M | |
Other Current Assets | 277.1B | 307.1B | 350.0K | 295.5K | 339.8K | 322.8K | |
Property Plant And Equipment Gross | 9.5M | 9.1M | 14.7M | 14.8M | 17.0M | 17.9M | |
Total Current Assets | 14.0M | 20.8M | 14.4M | 8.4M | 9.7M | 14.1M | |
Intangible Assets | 358.4K | 350.1K | 341.8K | 333.6K | 383.6K | 357.5K | |
Property Plant Equipment | 9.5M | 9.1M | 8.7M | 8.1M | 9.3M | 8.4M | |
Net Tangible Assets | 21.4M | 29.6M | 22.7M | 14.5M | 16.7M | 22.0M | |
Net Invested Capital | 22.9M | 30.0M | 23.2M | 14.9M | 17.1M | 22.5M |
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in NanoViricides. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in real. For information on how to trade NanoViricides Stock refer to our How to Trade NanoViricides Stock guide.You can also try the Transaction History module to view history of all your transactions and understand their impact on performance.
Complementary Tools for NanoViricides Stock analysis
When running NanoViricides' price analysis, check to measure NanoViricides' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy NanoViricides is operating at the current time. Most of NanoViricides' value examination focuses on studying past and present price action to predict the probability of NanoViricides' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move NanoViricides' price. Additionally, you may evaluate how the addition of NanoViricides to your portfolios can decrease your overall portfolio volatility.
Sync Your Broker Sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors. | |
Performance Analysis Check effects of mean-variance optimization against your current asset allocation | |
USA ETFs Find actively traded Exchange Traded Funds (ETF) in USA | |
Global Markets Map Get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes | |
Stocks Directory Find actively traded stocks across global markets | |
Odds Of Bankruptcy Get analysis of equity chance of financial distress in the next 2 years | |
Instant Ratings Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
Commodity Directory Find actively traded commodities issued by global exchanges | |
Analyst Advice Analyst recommendations and target price estimates broken down by several categories | |
Idea Analyzer Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas |
Is NanoViricides' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of NanoViricides. If investors know NanoViricides will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about NanoViricides listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.80) | Return On Assets (0.36) | Return On Equity (0.58) |
The market value of NanoViricides is measured differently than its book value, which is the value of NanoViricides that is recorded on the company's balance sheet. Investors also form their own opinion of NanoViricides' value that differs from its market value or its book value, called intrinsic value, which is NanoViricides' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because NanoViricides' market value can be influenced by many factors that don't directly affect NanoViricides' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between NanoViricides' value and its price as these two are different measures arrived at by different means. Investors typically determine if NanoViricides is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, NanoViricides' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.